Özet:

Metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAYKH) are among the major comorbidities of psoriasis. Visfatin is an adipokind that is released from the viseral white oil tissue. The levels increase in cases such as obesity and chronic inflammation. Our study examined the relationship between the level of serum visphatin and the presence of NAYKH with psoriasis and comorbiditis. Method: Our study included 80 patients with psoriasis, who apply to the Dermatology Clinic of the 18th March University of Çanakkale Medical School. Patients were divided into groups of 40 people with and without MS. A group of 40 people was involved in the work. The patient's back surroundings, the basin surroundings were measured. The body mass index and the area of psoriasis weight index values were calculated. The liver ultrasound was performed. The level of serum visphatin was measured by the ELISA method. Results: In comparison with the age and gender control group of non-MS patients with psoriasis in terms of serum visphatin levels, the levels of visphatin in psoriasis patients were statistically significantly higher (p<0,001). However, when compared patients with MS and non-psoriasis in terms of serum visphatin levels, there was no statistically significant difference between the two groups (p=0,980). However, there was no significant difference in the prevalence of NAYKH when compared with the healthy control group of patients with non-MS psoriasis (p=0,469). NAYKH was detected significantly higher in patients with psoriasis with MS and was seen more severe (p<0,001). Result: NAYKH prevalence has increased in patients with psoriasis, but no significant difference has been found in terms of NAYKH when compared with the control group with patients with psoriasis without MS. This situation supports the view that the increased prevalence of NAYKH in psoriasis may be directly related to the increased frequency of MS in psoriasis. In addition, serum visphatin levels were found significantly high in patients with psoriasis, but this height was independent of MS and its components. From this study, it can be concluded that the elevation of serum visphatin levels in psoriasis may be associated with chronic inflammation in psoriasis. Keywords: Psoriasis; Metabolic syndrome; Non-alcoholic fat liver disease; Adipokin; Visfatin ABSTRACT Objective: Psoriasis is frequently associated with comorbidities including metabolic syndrome and non-alcoholic fat liver disease. Visfatin is an adipokine secreted from adipocytes of white fat tissue and its high concentrations is known to be in a relationship with abdominal obesity and chronic inflammation. This study investigates serum levels of visfatin in patients with psoriasis therefore we consider how psoriasis is linked to metabolic syndrome and non-alcoholic fatty liver disease. Method: In this study, we evaluated 80 psoriasis patients which are requested Canakkale Eighth March University, Faculty of Medicine, Department of Dermatology outpatient clinic. They were divided into 2 groups as patients with metabolic syndrome and without diagnosis of metabolic syndrome. A healthy control group, 40 people are also included. The body mass index, waist and hip circumference were calculated. The score of psoriasis area severity index, grade of non-alcoholic fatty liver disease. Our patients are also undergo ultrasonographic liver screening. For quantification of the visfatin, ELISA based assay was used. Results: Visfatin levels were found statistically higher in the healthy (without metabolic syndrome) psoriasis group versus control group (p<0.001). Neither healthy psoriasis patients nor psoriasis patients with metabolic syndrome, a significant difference could be observed both groups (p=0,980). On the other hand, the prevalence of the non-alcoholic fatty liver disease has shown no difference between healthy controls and healthy psoriasis patients (p=0,469). Non-alcoholic fatty liver disease and the severity of hepatosteatosis were determined significantly higher in psoriasis patients with metabolic syndrome (p<0,001). Conclusion: The prevalence of non-alcholic fatty liver disease was observed to be higher in psoriasis patients. However there were no differences between controls and healthy psoriasis patients for prevalence of non-alcholic fatty liver disease. Therefore we think that this result supports the metabolic syndrome and psoriasis relationship. Visfatin levels detected significantly higher in psoriasis patients independently from metabolic syndrome and its components. These findings suggest that high visfatin levels might play a role in chronic inflammation seen in psoriasis. Keywords: Psoriasis; Metabolic syndrome; Non-alcoholic fatty liver disease; Adipokine; Visfatin